NCT04102982

Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer

Shandong Provincial Hospital Affiliated to Shandong University

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Shandong Provincial Hospital · Other Government
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Patients were randomized to microwave ablation plus camrelizumab group or camrelizumab group.

Detailed description

Patients in the camrelizumab group were treated with camrelizumab with the dose of 200mg on day 1, repeated every 21 days.Patients in the combination group were treated with MWA in the primary tumor followed by camrelizumab with the dose of 200mg on day 1, repeated every 21 days. The primary end point is overall survival. The second end points include progression free survival, objective response rate and safety.

Conditions

• NSCLC Stage IV

Interventions

Type	Name	Description
DRUG	Camrelizumab	Patients will be treated with camrelizumab alone.
OTHER	Camrelizumab plus microwave ablation	In the group, microwave ablation will be administrated to the primary tumors, followed by camrelizumab.

Timeline

• Start date: 2019-11-01
• Primary completion: 2021-10-31
• Completion: 2022-02-28
• First posted: 2019-09-25
• Last updated: 2020-11-02

Locations

13 sites across 1 country: China